Tag: personalized medicine
-
Andarix Pharmaceuticals Selected to Present at International Drug Conference in Copenhagen
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at www.orphandrugssummit.com. Mr. Adams will highlight recent results of…
-
Andarix Pharmaceuticals Receives Pancreatic Cancer Orphan Drug Designation from the FDA
Tozaride is a potential breakthrough therapy for pancreatic cancer because patients will first be screened with its companion diagnostic, and only those patients who may be positive responders to the drug will be treated. Pancreatic cancer is responsible for significant cancer mortality in the United States, with over 50,000 new diagnoses and over 50,000 deaths…
-
Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC).